HbO2 Therapeutics Email Format

Biotechnology ResearchPennsylvania, United States2-10 Employees

HbO2 Therapeutics develops and manufactures oxygen-carrying solutions intended to increase systemic oxygen transport when administered intravenously. The company has developed two products: Hemopure, a bovine hemoglobin glutamer-250 formulation for human use, and Oxyglobin, a bovine hemoglobin glutamer-200 product for veterinary use. Oxyglobin is the only oxygen-carrying solution approved by both the U.S. Food and Drug Administration and the European Medicines Agency to treat all-cause canine anemia. Hemopure has regulatory approvals in South Africa for adult surgical anemia and in the Russian Federation for acute anemia, while in the United States it is available only under FDA expanded-access programs for qualifying patients with severe, life-threatening anemia where transfusion is not an option. Based in Souderton, Pennsylvania, HbO2 Therapeutics operates in the biotechnology research space and focuses on medical and veterinary settings that require alternatives to transfusion. The company has pursued collaborations in development, such as with University Medical Center Groningen in 2019, reflecting its engagement with research partners.

Get verified HbO2 Therapeutics emails free

Company overview Employee directory